This is an equity-fundamental review of Linde India Ltd (industrial gases & engineering) as of 12 January 2026, based on publicly available data.

---

1. Business Snapshot

- Segment: Industrial, specialty & medical gases; on-site bulk gas supply; packaged gases; project engineering (air separation units, cryogenic equipment). (lindeindia.in)

- Parentage: Part of Linde plc, the world’s largest industrial gases group, giving strong technology, safety and process advantages. (lindeindia.in)

- Network: >35 operating locations, India’s largest air separation plant, strong bulk tanker and cylinder network. (lindeindia.in)

- Customer base: Steel, chemicals, autos, healthcare (medical oxygen & gases), food & beverages, electronics, etc.

Business quality is typically viewed as high: mission-critical product, long-term contracts, high switching costs, and strong parent backing.

---

2. Recent Financial Performance

FY25 (year ended March 2025 – consolidated)

- Revenue: ~₹2,485 crore, down ~10% YoY (from ~₹2,769 crore).

- Net profit: ~₹455 crore, up ~4.8% YoY (from ~₹434 crore). (business-standard.com)

- EPS (FY25): ~₹53.3 vs ₹50.9 in FY24. (indiratrade.com)

- Margins (FY25, consolidated):

- Core EBITDA margin ~30.6% (improved from ~25.2%).

- PAT margin ~18.3% (vs ~15.7% in FY24). (indiratrade.com)

Interpretation:

- Despite topline contraction (partly due to lower project revenues / price resets), profitability improved, indicating mix upgrade, better pricing and cost control.

- Structural margin profile is robust for an industrial company, helped by long-term on-site contracts and operating leverage.

Latest reported quarter – Sep 2025 (Q2 FY26, consolidated)

- Net sales: ~₹644 crore, +1.5% YoY (₹634 crore a year ago).

- Net profit: ~₹171 crore, +~60–61% YoY (₹106–107 crore a year ago).

- EBITDA: ~₹286 crore, +~46% YoY. (business-standard.com)

Interpretation:

- Growth in Q2 was margin-led rather than revenue-led – strong jump in EBITDA and PAT with only modest sales growth.

- Suggests operational efficiency, better product mix and possibly an improving high-margin healthcare / specialty gases contribution.

---

3. Balance Sheet & Quality Metrics

From recent ratio snapshots (FY25 consolidated): (rwsec.com)

- Debt: Practically debt-free – Total Debt/Equity ~0.

- Return ratios:

- ROE ~12.5% (down from ~18–20% in earlier high-growth periods).

- ROCE ~17–18%.

- Liquidity:

- Current ratio ~1.0–1.7 range over recent years (comfortable).

- Strong interest coverage (well above 40x historically).

- Dividend: DPS ₹12 per share for FY25 (similar to previous two years); yield is low given high share price.

Interpretation:

- Clean balance sheet with no financial leverage – typical for high-quality MNC industrial gas players in India.

- Return ratios remain healthy but not extraordinarily high, partly because of high capital intensity and subdued recent sales growth.

---

4. Strategic & Structural Drivers

1. Industrial gases as a “utility-like” business

- Long-duration contracts (10–15+ years) with large customers (steel, refineries, chemicals).

- High entry barriers: technology, safety, capex, approvals, and need for reliable 24x7 operations.

2. Healthcare & medical gases

- Medical oxygen, nitrous oxide, etc.

- Post-Covid, healthcare infrastructure and medical gas demand have structurally increased, though growth has normalized.

3. Electronics / Semiconductors opportunity

- Linde (group) is in advanced talks to set up a new plant in Dholera, Gujarat, to support the upcoming semiconductor ecosystem; this indicates intent to deepen presence in electronics gases in India. (economictimes.indiatimes.com)

- Over time, if semiconductor and electronics manufacturing scale up domestically, specialty gases could be a strong growth driver for Linde India.

4. Global parent’s technology & hydrogen / clean energy

- Linde plc is investing globally in hydrogen and decarbonization-related gases. (reuters.com)

- While the direct benefit to Linde India is still emerging, access to such technology positions the Indian arm to participate as domestic policies around green hydrogen and decarbonization evolve.

---

5. Key Risks

1. Cyclical exposure to industrial demand

- Slower steel, chemicals, or manufacturing cycles can dampen volume growth or delay new projects.

2. Concentration and contract renegotiations

- Large on-site plants are often tied to a few big customers; any renegotiation, closure, or technology shift at the customer end can impact utilization.

3. Regulatory & pricing constraints in medical gases

- Medical oxygen carries social and regulatory sensitivity; price caps or policy changes can affect margins.

4. Parent and global cycle

- Though Linde India’s operations are local, sentiment and capital allocation can be influenced by global macro headwinds (Europe in particular has seen weaker volumes for Linde globally). (reuters.com)

---

6. Valuation Snapshot (as of early January 2026)

From recent market data (NSE: LINDEINDIA): (stockanalysis.com)

- Share price: ~₹5,900 (closing around 9 January 2026; live price will differ).

- Market cap: ~₹50,400 crore.

- Valuation multiples (TTM / recent):

- Trailing P/E ~98x; forward P/E ~82x.

- P/B ~12–13x.

- Price-to-Sales (TTM) ~20x range; historical P/S moved from ~5–11x (pre-2022) to above 20x in recent years.

Interpretation:

- Valuation is rich by conventional industrial metrics and above its own long-term average (P/E and P/S have both re-rated sharply over the last few years). (rwsec.com)

- The market appears to be pricing:

- High business quality and parentage,

- Strong cash generation, debt-free balance sheet,

- Long-term structural growth from industrial, healthcare, and electronics/semiconductor gases.

- At such multiples, the stock is sensitive to any slowdown in earnings growth or delay in capex-led opportunities.

---

7. Analytical Summary (Not Investment Advice)

- Business quality: Strong – mission-critical products, high entry barriers, strong parent support, diversified industrial & healthcare exposure.

- Financials:

- FY25 showed profit growth despite revenue decline, via margin expansion.

- Latest quarter (Sep 2025) indicates margin-led PAT acceleration with modest topline growth.

- Balance sheet is virtually debt-free, with healthy ROE/ROCE and steady dividends.

- Growth visibility:

- Core industrial demand plus healthcare forms a solid base.

- Optionality from electronics/semiconductor and future hydrogen/clean-energy opportunities adds a medium- to long-term growth layer.

- Valuation:

- Current multiples (P/E ~100x, P/B ~12x+) are demanding and assume sustained high-quality compounding.

- Historically and versus many other industrial names, the stock trades at a substantial premium, which increases downside risk if growth falters.

This note is an analytical review for educational purposes and is not a buy/hold/sell recommendation. For any decision, investors typically align such fundamentals with their risk profile, return expectations, and portfolio allocation discipline.

If you have any further queries, please connect with us on 022-6290-10141 (Timings : 09.00 AM to 05.00 PM) or you can email us on info@cniinfoxchange.com